WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, January 12, 2015

FDA Approves Revolutionary Parkinson's Treatment and NPF is Helping Deliver It to You

National Parkinson Foundation - Breaking News
FDA Approves Revolutionary Parkinson's Treatment
and NPF is Helping Deliver It to You
The National Parkinson Foundation (NPF) is pleased to share that the U.S. Food and Drug Administration (FDA) has approved DUOPA™, developed by AbbVie Inc., as a treatment for people with advanced Parkinson's disease. DUOPA™ is a new approach to the delivery of carbidopa and levodopa for the treatment of the motor symptoms of Parkinson's disease; it is administered using a small, portable infusion pump that delivers carbidopa and levodopa directly into the small intestine.

Key Highlights about DUOPA™: 
  • DUOPA™ is the first and only treatment providing 16 continuous hours of carbidopa and levodopa for motor symptoms in advanced PD.
  • In a clinical trial, patients treated with DUOPA™ experienced significantly greater improvement in "off" time than patients treated with oral carbidopa-levodopa immediate release tablets. 
"The approval of the dopamine pump for the treatment of Parkinson's disease is a huge step forward for treatment of Parkinson's disease patients suffering from motor fluctuations and other disabling symptoms.,"said Dr. Michael S. Okun, NPF's National Medical Director. "We are very enthusiastic about this advance being made available to patients all over the United States."

"Due to the progressive nature of Parkinson's disease, it can be difficult to treat over time, especially in the advanced stages," said Joyce Oberdorf, NPF's President and CEO. "Our organization is encouraged by the introduction of a new therapy that may provide another treatment option for affected patients and families."

NPF is collaborating with AbbVie in the development and delivery of comprehensive training programs on DUOPA™ for NPF Centers of Excellence (COEs). NPF considers AbbVie's DUOPA™ product to be an important tool to address unmet clinical needs for advanced Parkinson’s patients. The one-day trainings will be held in the first quarter of 2015 to ensure COEs are among the first sites to be trained.  The trainings will include hands-on sessions to provide a strong foundation for key stakeholders involved in managing treatment with DUOPA™.
This news comes on the heels of last week's FDA approval of RYTARY™ (carbidopa and levodopa) extended-release capsules. If you have questions about either of these newly-approved Parkinson's treatments, NPF's Helpline is available at 1-800-4PD-INFO (1-800-473-4636) or helpline@parkinson.org.

No comments:

Post a Comment